Treatment for Patients with High Risk Polycythemia Vera (PV) or High Risk Essential Thrombocythemia (ET)

What we are studying

The purpose of this study is to look at the effectiveness of giving patients who have been diagnosed with ET and PV a study drug regimen using Aspirin and Pegylated Interferon Alfa-2a (instead of the standard treatment drug called Hydroxyurea), for whom this drug may not be suitable. The drug may not be suitable either because it is not adequately controlling the number of blood cells or some specific side effects occur. All subjects participating in this study will receive Aspirin as part of their study drug regimen.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • 18 years of age
  • Diagnosed with essential thrombocythemia (ET) or polycythemia vera (PV
  • Intolerant or resistant to Hydroxyurea

What is involved

  • 1 screening visit
  • Spleen measurement
  • Eye exam
  • Blood tests
  • Bone marrow aspiration/biopsy/cytogenetics
  • EKG
  • Take study drug for period of the study
  • Routine clinic visits

Compensation

None

Contact Information

Study Coordinator
Thomas Freeman
Email
thfreema@wakehealth.edu
Phone
336-713-6914

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.